Clinical Trials
Lung Cancer
10
Page 1 of 1
| KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy Disease/Condition: Non Small Cell Lung Cancer Principal Investigator: Daniel Morgensztern |
| A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Ascending Doses of AZD4547 in Patients with Advanced Solid Tumor Malignancies Disease/Condition: Advanced Solid Cancers Principal Investigator: Howard S Hochster |
| A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 Disease/Condition: Advanced Malignancies | Anaplastic Large Cell Lymphoma | Carcinoma, Non-Small-Cell Lung | Diffuse Large Cell Lymphoma | Inflammatory Myofibroblastic Tumors Principal Investigator: Scott Nicholas Gettinger |
| Phase I/IIa First Time in Human study of GSK2636771 in subjects with advanced solid tumors Disease/Condition: Breast Cancer (ER, PR, and HER2 negative) | Colorectal Cancer | Endometrial Cancer | Gastric Adenocarcinoma | Glioblastoma Multiforme | Head/ Neck Squamous Cell Carcinoma | Melanoma | Non-Small Cell Lung Cancer (NSCLC) | Ovarian Cancer | Prostate Cancer Principal Investigator: Roy Herbst |
| Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Disease/Condition: Non Small Cell Lung Cancer Principal Investigator: Roy Herbst |
| BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study Disease/Condition: Non Small Cell Lung Cancer Principal Investigator: Roy Herbst |
| Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery Disease/Condition: Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer | Stage IIIA Non-small Cell Lung Cancer Principal Investigator: Scott Nicholas Gettinger |
Page 1 of 1
